GHENT, BELGIUM--(Marketwire - January 06, 2010) - Ablynx [Euronext Brussels: ABLX] today announced that it will webcast its corporate presentation at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, 13 January 2010 at 11.00 a.m. PST / 08.00 p.m. CET.
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of Ablynx’s website at www.ablynx.com http://www.ablynx.com/. A replay of the webcast will also be available on the Company’s website for 30 days, by default (until 12 February 2010).
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com http://www.ablynx.com/
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 230 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Nanobodies have been generated against more than 150 different disease targets. Efficacy data have been obtained in over 26 in vivo models for Nanobodies against a range of different targets.
Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 50 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.
Ablynx has ongoing research collaborations and significant partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer (previously Wyeth Pharmaceuticals). Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies through these collaborations as well as through its own internal discovery programmes.
[HUG#1370935]
Complete version of the press release: http://hugin.info/137912/R/1370935/335363.pdf
For more information, please contact:
College Hill Life Sciences for International media enquiries:
Sue Charles, Justine Lamond
t:Â Â +44 (0)20 7866 7857
f:Â Â +44 (0)20 7866 7900
e:Â Email Contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t:Â Â +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:Â Email Contact
Eva-Lotta Allan
Chief Business Officer
t:Â Â +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:Â Email Contact
